肿瘤标志物联合检测在肺癌诊断中的临床价值  

Evaluation of clinical value of combined tumor markers detection in diagnosis of lung cancer

作　　者：张光明[1] 邓守真[1] 王赟[1] 徐莲琴 何婉婷 高泉[1] 林祥通[1] 

机构地区：[1]复旦大学附属华山医院,上海200040

出　　处：《核技术》2002年第5期380-382,共3页Nuclear Techniques

摘　　要：为探讨血清肿瘤标志物CY2 1 - 1、CEA、CA1 5 - 3、SCC单项检测及联合检测在肺癌诊断中的临床价值。对 87例经细胞学或组织病理学证实诊断为肺癌的住院患者入院时血清CY2 1 - 1、CEA、CA1 5 - 3及SCC检测结果进行了分析。结果表明 ,(1 )CY2 1 - 1、CEA、CA1 5 - 3及SCC单项检测对肺癌诊断的敏感度分别为 :5 9.8%、3 9.1 %、4 4.8%和 1 8.4 %。 (2 )联合检测对肺癌诊断的敏感度 :Ⅰ组 :CY2 1 - 1 +CEA为 78.2 % ,Ⅱ组 :CY2 1 - 1 +CEA +CA1 5 - 3为 88.5 % ,Ⅲ组 :CY2 1 - 1 +CEA +CA1 5 - 3To evaluate clinical value of single or combined tumor marker detection CY21-1, CEA, CA15-3 and SCC in the diagnosis of lung cancer. There was retrospective analysis of 87 lung cancer in-patients, all of them was confirmed by pathology. Result showed: (1) Sensitivity of CY21-1, CEA, CA15-3 and SCC by single detection in diagnosing lung cancer was 59.8%, 39.1%, 44.8%, 18.4%, respectively. (2) Sensitivity of groupⅠ (CY21-1+CEA) was 78.2%; sensitivity of group Ⅱ (CY21-1+CEA+CA15-3)was 88.5%; sensitivity of group Ⅲ (CY21-1+CEA+CA15-3+SCC) was the same as group Ⅱ. In the diagnosis of lung cancer, the combined detection with CY21-1, CEA, CA15-3 was an ideal selective combination.

关 键 词：联合检测 临床价值 肿瘤标志物 肺癌 诊断 血清 

分 类 号：R734.2[医药卫生—肿瘤] R730.44[医药卫生—临床医学]